Will 2017 be the year William Ackman’s Perching Square Capital finds near term performance mean reversion? The $11.6 billion activist hedge fund, dragging near the bottom of HSBC’s Hedge Weekly performance listing the previous two years, started 2017 with some good news on his Herbalife short exposure. The stock the fund famously loves to hate, shorted in May of 2012 near $48 per share, has finally moved lower to near break even as government regulators force it to pay its distributors. But will the Trump administration, with top adviser Carl Icahn significantly long Herbalife, be a disaster for Ackman's short thesis?
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full ArticleAlready a member? Log in here
